Literature DB >> 27801970

The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site.

P van Doorn1, J Rosing1, S J Wielders1, T M Hackeng1, E Castoldi1.   

Abstract

Essentials The C-terminus of tissue factor pathway inhibitor (TFPIα) binds to the B-domain of factor V (FV). The functional consequences of this interaction were investigated in plasma and model systems. The TFPIα C-terminus inhibited thrombin generation in plasma, but not in the presence of FVa. The TFPIα C-terminus inhibited FV activation by preventing cleavage at Arg1545 .
SUMMARY: Background Factor V (FV) is a carrier and a cofactor of the anticoagulant protein tissue factor pathway inhibitor-α (TFPIα), whose basic C-terminus binds to an acidic region in the B-domain of FV. Proteolysis of FV at Arg709 , Arg1018 and Arg1545 by activated FX (FXa) or thrombin removes the B-domain, and converts FV into a procoagulant cofactor (activated FV [FVa]) of FXa in the prothrombinase complex. However, retention of the acidic region in partially activated FV makes prothrombinase activity susceptible to inhibition by TFPIα. Objective/Methods To investigate the effect of the TFPIα C-terminal peptide (TFPIα C-term) on thrombin generation in plasma and on FV activation in model systems. Results TFPIα C-term inhibited tissue factor-initiated and FXa-initiated thrombin generation in a dose-dependent manner. Failure to inhibit thrombin generation in FV-depleted plasma reconstituted with FVa indicated that the peptide effect was mediated by the acidic region of FV, and was localized at the level of FV activation and/or prothrombinase. In model systems, TFPIα C-term inhibited both FV activation and prothrombinase activity. Western blot analysis showed that the peptide impaired cleavage at Arg1545 by both thrombin and FXa. The inhibition was stronger for FV-short, which binds TFPIα with higher affinity. Similar results were obtained with full-length TFPIα. Conclusions Cleavage of FV at Arg1545 , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIα C-terminus to the FV acidic region. Possible targets of this new anticoagulant function of TFPIα are low-abundance FV(a) species retaining the acidic region.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  factor V; factor Xa; prothrombinase complex; thrombin; tissue factor pathway inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27801970     DOI: 10.1111/jth.13559

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  13 in total

1.  Factor V east Texas variant causes bleeding in a three-generation family.

Authors:  Julie A Peterson; Sweta Gupta; Nicholas D Martinez; Brandon Hardesty; Susan A Maroney; Alan E Mast
Journal:  J Thromb Haemost       Date:  2021-12-07       Impact factor: 5.824

2.  Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.

Authors:  Paul E R Ellery; Ida Hilden; Peter Thyregod; Nicholas D Martinez; Susan A Maroney; Joan C Gill; Alan E Mast
Journal:  Haemophilia       Date:  2019-10-14       Impact factor: 4.287

3.  TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.

Authors:  Jeremy P Wood; Helle H Petersen; Bingke Yu; Xiaoai Wu; Ida Hilden; Alan E Mast
Journal:  Blood Adv       Date:  2017-12-26

4.  Platelet anticoagulant proteins: Modulators of thrombosis propensity within a procoagulant cell.

Authors:  Amy E Siebert; Alan E Mast
Journal:  J Thromb Haemost       Date:  2020-07-30       Impact factor: 5.824

5.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

6.  Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Authors:  M Ibrahim-Kosta; P Suchon; F Couturaud; D Smadja; R Olaso; M Germain; N Saut; L Goumidi; C Derbois; F Thibord; S Debette; P Amouyel; J F Deleuze; P van Doorn; E Castoldi; E Patin; M C Alessi; D A Trégouët; P E Morange
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

7.  Hydrogen Attenuates Endotoxin-Induced Lung Injury by Activating Thioredoxin 1 and Decreasing Tissue Factor Expression.

Authors:  Qian Li; Liang Hu; Juan Li; Pan Yu; Fan Hu; Bing Wan; Miaomiao Xu; Huixian Cheng; Wanyou Yu; Liping Jiang; Yadan Shi; Jincan Li; Manlin Duan; Yun Long; Wen-Tao Liu
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

Review 8.  Impact of Acute and Chronic Stress on Thrombosis in Healthy Individuals and Cardiovascular Disease Patients.

Authors:  Leonardo Sandrini; Alessandro Ieraci; Patrizia Amadio; Marta Zarà; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

9.  Thrombin generation abnormalities in Quebec platelet disorder.

Authors:  Justin G Brunet; Tanmya Sharma; Subia Tasneem; Minggao Liang; Michael D Wilson; Georges E Rivard; Catherine P M Hayward
Journal:  Int J Lab Hematol       Date:  2020-08-06       Impact factor: 2.877

10.  Tissue factor pathway inhibitor is required for cerebrovascular development in mice.

Authors:  Susan A Maroney; Randal J Westrick; Audrey C Cleuren; Nicholas D Martinez; Amy E Siebert; Mark Zogg; David Ginsburg; Hartmut Weiler; Alan E Mast
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.